Date:202	3.01.10
Your Name:	Lin Shi
Manuscript Title:_	Circ_0003028 enhances the proliferation and glycolytic capacity and suppresses apoptosis in non-
small cell lung can	cer cells via the miR-1305/miR-1322-SLC5A1 axis
Manuscript number	er (if known):

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The following questions apply to the author's relationships/activities/interests as they relate to the <u>current manuscript only</u>.

The author's relationships/activities/interests should be <u>defined broadly</u>. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

		Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)
		Time frame: Since the initial	planning of the work
1	All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.)  No time limit for this item.	XNone	
		Time frame: past	36 months
2	Grants or contracts from any entity (if not indicated in item #1 above).	XNone	
3	Royalties or licenses	XNone	
4	Consulting fees	XNone	

5	Payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing or educational events	XNone	
6	Payment for expert testimony	XNone	
7	Support for attending meetings and/or travel	<b>X</b> None	
8	Patents planned, issued or pending	XNone	
9	Participation on a Data Safety Monitoring Board or Advisory Board	XNone	
10	Leadership or fiduciary role in other board, society, committee or advocacy group, paid or unpaid	XNone	
11	Stock or stock options	XNone	
12	Receipt of equipment, materials, drugs, medical writing, gifts or other services	XNone	
13	Other financial or non- financial interests	XNone	
	ease summarize the above co	onflict of interest in the foll	owing box:

	ICMJE DISC	LOSURE FORM	
Date: 2023.01.10			
	nyuan Huang		
Manuscript Title: Circ_0 small cell lung cancer cells via Manuscript number (if known	003028 enhances the prolif a the miR-1305/miR-1322-S	eration and glycolytic capacity and suppresses apoptosis LC5A1 axis	in nor
related to the content of you parties whose interests may	r manuscript. "Related" me be affected by the content of t necessarily indicate a bias.	I relationships/activities/interests listed below that are ans any relation with for-profit or not-for-profit third of the manuscript. Disclosure represents a commitment. If you are in doubt about whether to list a poso.	
The following questions appl manuscript only.	y to the author's relationsh	ips/activities/interests as they relate to the <u>current</u>	
to the epidemiology of hyper medication, even if that med	tension, you should declare ication is not mentioned in upport for the work reporte	defined broadly. For example, if your manuscript pertain all relationships with manufacturers of antihypertensive the manuscript.  End in this manuscript without time limit. For all other ite	е
	Name all entities with whom you have this	Specifications/Comments (e.g., if payments were made to you or to your	
	relationship or indicate none (add rows as needed)	institution)	
	Time frame: Since the initia	l planning of the work	
All support for the present	X None		

		Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments  (e.g., if payments were made to you or to your institution)
		Time frame: Since the initial	planning of the work
1	All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.)  No time limit for this item.	XNone	
		Time frame: past	36 months
2	Grants or contracts from any entity (if not indicated in item #1 above).	XNone	
3	Royalties or licenses	XNone	
4	Consulting fees	XNone	

5	Payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing or educational events	XNone	
6	Payment for expert testimony	XNone	
7	Support for attending meetings and/or travel	<b>X</b> None	
8	Patents planned, issued or pending	XNone	
9	Participation on a Data Safety Monitoring Board or Advisory Board	XNone	
10	Leadership or fiduciary role in other board, society, committee or advocacy group, paid or unpaid	XNone	
11	Stock or stock options	XNone	
12	Receipt of equipment, materials, drugs, medical writing, gifts or other services	XNone	
13	Other financial or non- financial interests	XNone	
	ease summarize the above co	onflict of interest in the foll	owing box:

	iding piocessine i dini
Date:2023.	01.10
	Shaobing Chen
Manuscript Title:	Circ_0003028 enhances the proliferation and glycolytic capacity and suppresses apoptosis in nor rells via the miR-1305/miR-1322-SLC5A1 axis
Manuscript number	(if known):
related to the conterparties whose interes to transparency and	nsparency, we ask you to disclose all relationships/activities/interests listed below that are not of your manuscript. "Related" means any relation with for-profit or not-for-profit third ests may be affected by the content of the manuscript. Disclosure represents a commitment does not necessarily indicate a bias. If you are in doubt about whether to list a /interest, it is preferable that you do so.
The following questi manuscript only.	ons apply to the author's relationships/activities/interests as they relate to the <u>current</u>
The author's relation	oshins/activities/interests should be defined broadly. For example, if your manuscript pertains

The author's relationships/activities/interests should be <u>defined broadly</u>. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

		Name all entities with whom you have this relationship or indicate none (add rows as needed) Time frame: Since the initial	Specifications/Comments (e.g., if payments were made to you or to your institution)  planning of the work
1	All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.)  No time limit for this item.	XNone	
		Time frame: past	36 months
2	Grants or contracts from any entity (if not indicated in item #1 above).	XNone	
3	Royalties or licenses	XNone	
4	Consulting fees	XNone	

5	Payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing or educational events	XNone	
6	Payment for expert testimony	XNone	
7	Support for attending meetings and/or travel	<b>X</b> None	
8	Patents planned, issued or pending	XNone	
9	Participation on a Data Safety Monitoring Board or Advisory Board	XNone	
10	Leadership or fiduciary role in other board, society, committee or advocacy group, paid or unpaid	XNone	
11	Stock or stock options	XNone	
12	Receipt of equipment, materials, drugs, medical writing, gifts or other services	XNone	
13	Other financial or non- financial interests	XNone	
	ease summarize the above co	onflict of interest in the foll	owing box:

		ICMJE DISCL	OSURE FORM			
Dat	re: 2023.01.10					
		 n Wang				
Ma sma	our Name: Siyun Wang anuscript Title: Circ_0003028 enhances the proliferation and glycolytic capacity and suppresses apoptosis in non- nall cell lung cancer cells via the miR-1305/miR-1322-SLC5A1 axis anuscript number (if known):					
rela par to t	ated to the content of your ties whose interests may b cransparency and does not	manuscript. "Related" mea e affected by the content o	relationships/activities/interests listed below that arens any relation with for-profit or not-for-profit third of the manuscript. Disclosure represents a commitment of you are in doubt about whether to list a			
	e following questions apply nuscript only.	to the author's relationshi	ps/activities/interests as they relate to the <u>current</u>			
to t	he epidemiology of hypert	•	defined broadly. For example, if your manuscript persall relationships with manufacturers of antihypertensible manuscript.			
	tem #1 below, report all su time frame for disclosure	• •	d in this manuscript without time limit. For all other	items,		
		Name all entities with	Specifications/Comments			
		whom you have this	(e.g., if payments were made to you or to your			
		relationship or indicate	institution)			
		none (add rows as needed)				
		Time frame: Since the initial	planning of the work			
	All support for the present	XNone				

Time frame: past 36 months

**X** \_\_None

**X**\_None

X \_\_None

manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.) No time limit for this item.

Grants or contracts from any entity (if not indicated

in item #1 above).

Consulting fees

Royalties or licenses

2

3

4

5	Payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing or educational events	XNone	
6	Payment for expert testimony	XNone	
7	Support for attending meetings and/or travel	<b>X</b> None	
8	Patents planned, issued or pending	XNone	
9	Participation on a Data Safety Monitoring Board or Advisory Board	XNone	
10	Leadership or fiduciary role in other board, society, committee or advocacy group, paid or unpaid	XNone	
11	Stock or stock options	XNone	
12	Receipt of equipment, materials, drugs, medical writing, gifts or other services	XNone	
13	Other financial or non- financial interests	XNone	
	ease summarize the above co	onflict of interest in the foll	owing box:

Date:	2023.01.10
Your Name:_	Chenxin Yan
Manuscript 1	Title: Circ_0003028 enhances the proliferation and glycolytic capacity and suppresses apoptosis in non
small cell lun	ng cancer cells via the miR-1305/miR-1322-SLC5A1 axis
Manuscript r	number (if known):
related to th parties whos to transpare	st of transparency, we ask you to disclose all relationships/activities/interests listed below that are see content of your manuscript. "Related" means any relation with for-profit or not-for-profit third see interests may be affected by the content of the manuscript. Disclosure represents a commitment ncy and does not necessarily indicate a bias. If you are in doubt about whether to list a /activity/interest, it is preferable that you do so.

The following questions apply to the author's relationships/activities/interests as they relate to the <u>current manuscript only</u>.

The author's relationships/activities/interests should be <u>defined broadly</u>. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

		Name all entities with whom you have this relationship or indicate none (add rows as needed)  Time frame: Since the initial	Specifications/Comments  (e.g., if payments were made to you or to your institution)
1	All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.)  No time limit for this item.	XNone	
		Time frame: past	36 months
2	Grants or contracts from any entity (if not indicated in item #1 above).	XNone	
3	Royalties or licenses	XNone	
4	Consulting fees	XNone	

5	Payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing or educational events	XNone	
6	Payment for expert testimony	XNone	
7	Support for attending meetings and/or travel	<b>X</b> None	
8	Patents planned, issued or pending	XNone	
9	Participation on a Data Safety Monitoring Board or Advisory Board	<b>X</b> None	
10	Leadership or fiduciary role in other board, society, committee or advocacy group, paid or unpaid	<b>X</b> None	
11	Stock or stock options	XNone	
12	Receipt of equipment, materials, drugs, medical writing, gifts or other services	XNone	
13	Other financial or non- financial interests	XNone	
	ease summarize the above co	onflict of interest in the fol	lowing box:

Date:	2023.01.10
Your Name:_	Xiaofei Chen
-	Fitle: Circ_0003028 enhances the proliferation and glycolytic capacity and suppresses apoptosis in non- neg cancer cells via the miR-1305/miR-1322-SLC5A1 axis
Manuscript r	number (if known):
related to th parties whos to transpare	st of transparency, we ask you to disclose all relationships/activities/interests listed below that are e content of your manuscript. "Related" means any relation with for-profit or not-for-profit third e interests may be affected by the content of the manuscript. Disclosure represents a commitment ncy and does not necessarily indicate a bias. If you are in doubt about whether to list a 'activity/interest, it is preferable that you do so.

The following questions apply to the author's relationships/activities/interests as they relate to the <u>current</u> <u>manuscript only</u>.

The author's relationships/activities/interests should be <u>defined broadly</u>. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

		Name all entities with whom you have this relationship or indicate none (add rows as needed)  Time frame: Since the initial	Specifications/Comments  (e.g., if payments were made to you or to your institution)
1	All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.)  No time limit for this item.	XNone	
		Time frame: past	36 months
2	Grants or contracts from any entity (if not indicated in item #1 above).	XNone	
3	Royalties or licenses	XNone	
4	Consulting fees	XNone	

5	Payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing or educational events	XNone	
6	Payment for expert testimony	XNone	
7	Support for attending meetings and/or travel	<b>X</b> None	
8	Patents planned, issued or pending	XNone	
9	Participation on a Data Safety Monitoring Board or Advisory Board	<b>X</b> None	
10	Leadership or fiduciary role in other board, society, committee or advocacy group, paid or unpaid	<b>X</b> None	
11	Stock or stock options	XNone	
12	Receipt of equipment, materials, drugs, medical writing, gifts or other services	XNone	
13	Other financial or non- financial interests	XNone	
	ease summarize the above co	onflict of interest in the fol	lowing box:

Date:	
Your Name	Bei Zhang
•	Title: Circ_0003028 enhances the proliferation and glycolytic capacity and suppresses apoptosis in non ng cancer cells via the miR-1305/miR-1322-SLC5A1 axis
Manuscript	number (if known):
related to t	est of transparency, we ask you to disclose all relationships/activities/interests listed below that are he content of your manuscript. "Related" means any relation with for-profit or not-for-profit third use interests may be affected by the content of the manuscript. Disclosure represents a commitment

The following questions apply to the author's relationships/activities/interests as they relate to the <u>current</u> manuscript only.

to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a

relationship/activity/interest, it is preferable that you do so.

The author's relationships/activities/interests should be <u>defined broadly</u>. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

		Name all entities with whom you have this relationship or indicate none (add rows as needed) Time frame: Since the initial	Specifications/Comments (e.g., if payments were made to you or to your institution)  planning of the work
1	All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.)  No time limit for this item.	XNone	
		Time frame: past	36 months
2	Grants or contracts from any entity (if not indicated in item #1 above).	XNone	
3	Royalties or licenses	XNone	
4	Consulting fees	XNone	

5	Payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing or educational events	XNone	
6	Payment for expert testimony	XNone	
7	Support for attending meetings and/or travel	<b>X</b> None	
8	Patents planned, issued or pending	XNone	
9	Participation on a Data Safety Monitoring Board or Advisory Board	<b>X</b> None	
10	Leadership or fiduciary role in other board, society, committee or advocacy group, paid or unpaid	<b>X</b> None	
11	Stock or stock options	XNone	
12	Receipt of equipment, materials, drugs, medical writing, gifts or other services	XNone	
13	Other financial or non- financial interests	XNone	
	ease summarize the above co	onflict of interest in the fol	lowing box:

	ICMJE DISCLOSURE FORM							
Da	te: 2023.01.10							
	ur Name: Bin I	<del></del> Ке						
Ma sm	Manuscript Title: Circ_0003028 enhances the proliferation and glycolytic capacity and suppresses apoptosis in non-small cell lung cancer cells via the miR-1305/miR-1322-SLC5A1 axis  Manuscript number (if known):							
rel pa to	ated to the content of your rties whose interests may b	manuscript. "Related" mea e affected by the content o necessarily indicate a bias.	relationships/activities/interests listed below that a ins any relation with for-profit or not-for-profit third f the manuscript. Disclosure represents a commitme If you are in doubt about whether to list a so.					
	e following questions apply anuscript only.	to the author's relationshi	ps/activities/interests as they relate to the current					
to	•	ension, you should declare	defined broadly. For example, if your manuscript per all relationships with manufacturers of antihyperter he manuscript.					
	In item #1 below, report all support for the work reported in this manuscript without time limit. For all other items, the time frame for disclosure is the past 36 months.							
		Name all entities with	Specifications/Comments					
		whom you have this	(e.g., if payments were made to you or to your					
		relationship or indicate	institution)					
		none (add rows as						
		needed)						
		Time frame: Since the initial	planning of the work					
L	All support for the present	<b>X</b> None						
	manuscript (e.g., funding,							

Time frame: past 36 months

**X** \_\_None

**X**\_None

X \_\_None

provision of study materials, medical writing, article processing charges, etc.) **No time limit for this item.** 

Grants or contracts from any entity (if not indicated

in item #1 above).

Consulting fees

Royalties or licenses

2

3

4

5	Payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing or educational events	XNone	
6	Payment for expert testimony	XNone	
7	Support for attending meetings and/or travel	<b>X</b> None	
8	Patents planned, issued or pending	XNone	
9	Participation on a Data Safety Monitoring Board or Advisory Board	<b>X</b> None	
10	Leadership or fiduciary role in other board, society, committee or advocacy group, paid or unpaid	<b>X</b> None	
11	Stock or stock options	XNone	
12	Receipt of equipment, materials, drugs, medical writing, gifts or other services	XNone	
13	Other financial or non- financial interests	XNone	
	ease summarize the above co	onflict of interest in the fol	lowing box: